RecruitingPriority 4 · Lower priorityNCT07624838
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Plain-language summary
This study is evaluating Brentuximab Vedotin Plus CHP as a treatment for people newly diagnosed with a type of T-cell lymphoma called AITL. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brentuximab Vedotin Plus CHP (DRUG): Brentuximab vedotin administered in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) as first-line treatment according to routine clinical practice. The treatment was prescribed by the treating physician as part of standard medical care and was not assigned or modified by the study
- Drugs / treatments
- Brentuximab Vedotin Plus CHP
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details